209 related articles for article (PubMed ID: 16198568)
1. Special issues related to breast cancer adjuvant therapy in older women.
Witherby SM; Muss HB
Breast; 2005 Dec; 14(6):600-11. PubMed ID: 16198568
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant treatment of elderly breast cancer patients.
Muss HB
Breast; 2007 Dec; 16 Suppl 2():S159-65. PubMed ID: 17728133
[TBL] [Abstract][Full Text] [Related]
3. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer in older women.
Muss HB
Semin Oncol; 1996 Feb; 23(1 Suppl 2):82-8. PubMed ID: 8614851
[TBL] [Abstract][Full Text] [Related]
5. Special issues related to the adjuvant therapy in very young women.
Aebi S
Breast; 2005 Dec; 14(6):594-9. PubMed ID: 16185868
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort.
Elkin EB; Hurria A; Mitra N; Schrag D; Panageas KS
J Clin Oncol; 2006 Jun; 24(18):2757-64. PubMed ID: 16782916
[TBL] [Abstract][Full Text] [Related]
8. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
Naeim A; Keeler EB
Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
[TBL] [Abstract][Full Text] [Related]
9. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
10. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
11. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
12. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
[TBL] [Abstract][Full Text] [Related]
13. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
14. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
Dodwell D; Williamson D
Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
[TBL] [Abstract][Full Text] [Related]
15. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society.
Ahn SH; Son BH; Kim SW; Kim SI; Jeong J; Ko SS; Han W;
J Clin Oncol; 2007 Jun; 25(17):2360-8. PubMed ID: 17515570
[TBL] [Abstract][Full Text] [Related]
16. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Kaufmann M; Rody A
Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
[TBL] [Abstract][Full Text] [Related]
17. Extended adjuvant endocrine therapy of early breast cancer.
Chowdhury S; Ellis P
Curr Med Res Opin; 2005 Dec; 21(12):1985-95. PubMed ID: 16368050
[TBL] [Abstract][Full Text] [Related]
18. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
Honma N; Horii R; Iwase T; Saji S; Younes M; Takubo K; Matsuura M; Ito Y; Akiyama F; Sakamoto G
J Clin Oncol; 2008 Aug; 26(22):3727-34. PubMed ID: 18669459
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
[TBL] [Abstract][Full Text] [Related]
20. A question of duration: do patients with early-stage breast cancer need more than five years of adjuvant endocrine therapy?
Burdette-Radoux S; Muss HB
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S37-41. PubMed ID: 19561005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
